

Army Drug Development program.

Registry No. 4a, 127914-02-7; 4b, 127914-17-4; 4c, 127914-18-5; 5, 886-64-6; 6, 107-95-9; 7, 127914-03-8; 8a, 127914-04-9; 8b, 127914-19-6; 8c, 127943-56-0; 9a, 127914-05-0; 9b, 127914-20-9; 9c, 127914-21-0; 10a, 127914-06-1; 10b, 127914-22-1; 10c, 127914-23-2; 11a, 127914-07-2; 11b, 127914-29-8; 12a, 127914-08-3;

12b, 127914-24-3; 13a, 127914-09-4; 13b, 127914-25-4; 14, 65194-10-7; 15, 127914-10-7; 15-HCl, 127914-26-5; 16a, 127914-11-8; 17a, 127914-12-9; 18a, 127914-13-0; 18b, 127914-27-6; 19, 127914-14-1; 20, 127914-15-2; 21, 127914-16-3; Cl(CH₂)₂OCOCl, 627-11-2; Cl(CH₂)₂OCONH(CH₂)₂COCl, 127914-28-7; MeNH₂, 74-89-5; H₂N(CH₂)₂NH₂, 107-15-3; 2-oxazolidinone, 497-25-6; acrylonitrile, 107-13-1.

Synthesis and Evaluation of Novel Electrophilic Nitrofurans Carboxamides and Carboxylates as Radiosensitizers and Biochemically Activated Cytotoxins

Matthew A. Naylor,* Miriam A. Stephens, Shirley Cole, Michael D. Threadgill,[†] Ian J. Stratford, Peter O'Neill, E. Martin Fielden, and Gerald E. Adams

Medical Research Council Radiobiology Unit, Chilton, Didcot, Oxon OX11 0RD, U.K. Received January 22, 1990

A series of 5-nitrofurans-2- and 3-carboxamides bearing alkylating side-chains has been synthesized and tested for their ability to radiosensitize selectively hypoxic Chinese hamster cells (V79) to the lethal effects of ionizing radiation and also for their ability to act directly and selectively as cytotoxic drugs on hypoxic V79 cells. The compounds were extremely efficient radiosensitizers of such cells in vitro and were more efficient than known nitroimidazoles of similar type. Their efficiencies as radiosensitizers correlated with their high electron affinity (E_1^0) as measured by pulse-radiolysis. However the compounds showed little radiosensitizing activity towards KHT sarcomas in C3H mice. The compounds in this series of nitrofurans were generally more toxic towards hypoxic cells than towards oxic cells in vitro but were less effective upon the basis of a differential effect than were similar nitroimidazoles reported previously.

Nitroheterocyclic compounds can act as radiosensitizers of hypoxic cells and as biochemically activated cytotoxins.¹ Radiosensitization is a fast, free-radical process, and a correlation has been observed between the one-electron reduction potentials (E_1^0) of a large number of chemically diverse nitroheterocycles and their ability to act as radiosensitizers of hypoxic cells.^{2,3} Nitro compounds can be reductively metabolized to form highly potent cytotoxins. Since biochemically activation occurs more readily in hypoxic tissue, there is a sound basis for a high degree of specificity in poorly oxygenated solid tumors.


Both the biochemically activity and radiosensitizing efficiency of 2-nitroimidazoles can be greatly increased by incorporating monofunctional alkylating groups into the molecule. One of the first examples of such a compound was α -(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU-1069, 1),^{4,5} a 2-nitroimidazole bearing an aziridine (Figure 1). This compound is about 5–10-fold more efficient than misonidazole (a related nitroimidazole not containing an alkylating group) as a radiation sensitizer of experimental tumors and shows considerably more cytotoxicity when reductively metabolized under hypoxic conditions. Preliminary clinical investigation of RSU-1069 has revealed gastrointestinal toxicity which restricts doses to levels not likely to produce significant radiosensitization.⁶ Various analogues have been synthesized and evaluated in attempts to reduce toxicity towards normal tissues without a corresponding reduction in radiosensitization of tumors. Examples include compounds in which the aziridine group is deactivated by substitution.⁷ Lower toxicity can also be achieved by using a prodrug of RSU-1069 such as the new and recently reported compound α -[[(2-bromoethyl)amino]methyl]-2-nitro-1H-imidazole-1-ethanol hydrobromide (RB-6145, 2).⁸

Increasing therapeutic benefit can also be achieved by increasing radiosensitizing potency. One possible way of obtaining this is to raise the redox potential of the nitro-


heterocycle. For example 5-nitrofurans are generally more electron affinic than 2-nitroimidazoles and both 5-nitro-2-furaldehyde semicarbazone (nitrofurazone, 3) and 5-nitro-2-furaldoxime (nifuroxime, 4) have been found to be very effective radiosensitizers of hypoxic cells in tissue culture systems.^{9,10} We have investigated nitrofurans bearing alkylating side-chains, and with E_1^0 values of between -210 and -350 mV (ie; both higher and lower E_1^0 than the known nonalkylating sensitizer nitrofurazone, 3) by altering the patterns of substitution. Of particular importance is the position of the nitro group on the furan ring and possible conjugation with electron withdrawing substituents. Changes in the nature of the substituents likely to have an effect on electron affinity have also been investigated. This paper describes studies with the nitrofurans having the highest (most positive) electron affinities of those synthesized, namely the 5-nitrofurans carboxamides and propenamides bearing side chains of varying electrophilic reactivity.

- (1) Collected papers in *Biochem. Pharmacol.* 1986, 35, 1-122 (Eds. Alexander, P., Gielen, J., Sartorelli, A. C.).
- (2) Adams, G. E.; Clarke, E. D.; Flockhart, I. R.; Jacobs, R. S.; Sehmi, D. S.; Stratford, I. J.; Wardman, P.; Watts, M. E.; Parrick, J.; Wallace, R. G.; Smithen, C. E. *Int. J. Radiat. Biol.* 1979, 35, 133.
- (3) Adams, G. E.; Flockhart, I. R.; Smithen, C. E.; Stratford, I. J.; Wardman, P.; Watts, M. E. *Radiat. Res.* 1976, 67, 9.
- (4) Adams, G. E.; Ahmed, I.; Sheldon, P. W.; Stratford, I. J. *Br. J. Cancer* 1984, 49, 571.
- (5) Adams, G. E.; Ahmed, I.; Sheldon, P. W.; Stratford, I. J. *Int. J. Radiat. Oncol. Biol. Phys.* 1984, 10, 1653.
- (6) Horwich, A.; Holliday, S. B.; Deacon, J. M.; Peckham, M. J. *Br. J. Radiol.* 1986, 59, 1238.
- (7) Ahmed, I.; Jenkins, T. C.; Walling, J. M.; Stratford, I. J.; Sheldon, P. W.; Adams, G. E.; Fielden, E. M. *Int. J. Radiat. Oncol. Biol. Phys.* 1986, 12, 1079.
- (8) Jenkins, T. C.; Naylor, M. A.; O'Neill, P.; Threadgill, M. D.; Cole, S.; Stratford, I. J.; Adams, G. E.; Fielden, E. M.; Suto, M. J.; Stier, M. A. *J. Med. Chem.*, in press.
- (9) Chapman, J. D.; Reuvers, A. P.; Borsa, J.; Petkau, A.; McCalla, D. R. *Cancer Res.* 1972, 32, 2618.
- (10) Sutherland, R. M.; Durand, R. E. *Int. J. Radiat. Biol.* 1972, 22, 613.

[†] Present address: School of Pharmacy, University of Bath, Bath, BA2 7AY, U.K.

Scheme I^a

^a Reagents: (i) SOCl_2/DMF ; (ii) $\text{RNH}_2/\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$; (iii) allyl alcohol/ $\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$; (iv) MCPBA/ CH_2Cl_2 ; (v) 2,2-dimethylaziridine/THF; (vi) *cis*-2,3-dimethylaziridine/THF; (vii) HBr (aq).

Scheme II^a

^a Reagents: (i) $\text{Ac}_2\text{O}/\text{NaOAc}$; (ii) $\text{Ac}_2\text{O}/\text{HNO}_3$; (iii) allylamine/ $\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$; (iv) MCPBA/ CH_2Cl_2 ; (v) 2,2-dimethylaziridine/THF; (vi) *cis*-2,3-dimethylaziridine/THF/MCPBA/ Et_3N .




Figure 1.

Chemistry

The common starting material for the series of 5-nitro-2-furyl derivatives 15–23 (of which, 15 has been reported previously¹¹) was 5-nitro-2-furyl chloride, prepared from commercially available 5-nitro-2-furoic acid (5) by treatment with refluxing thionyl chloride in the presence of a catalytic amount of dimethylformamide (DMF). Subsequent amides or esters were then prepared directly from this intermediate with the appropriate alcohol or amine (Scheme I).

Compounds 24–28 were prepared from the common starting material 5-nitro-2-furylacrylic acid (9), prepared

by Perkin condensation from 5-nitro-2-furaldehyde (7) with acetic anhydride/sodium acetate or directly by nitration of 2-furylacrylic acid (8). Corresponding propenamides (of which, 24 has been reported previously as an antibacterial agent¹²) were then prepared from the acyl chloride (Scheme II).

Compounds 29 and 30 were prepared by nitration of 2-methyl-3-furoic acid (11) according to the procedure of Gilman et al.,¹³ followed by coupling to allylamine by a mixed anhydride method. This coupling was used owing to the instability of 2-methyl-5-nitro-2-furoic acid (12) in the presence of thionyl chloride. The 3-nitro analogue 31 was prepared from 2-methyl-5-furoic acid by nitration of the methyl ester (13) according to the method of Rinkes,¹⁴ followed by direct coupling of the hydrolyzed ester (14) with allylamine (Scheme III).


Oxiranes 16, 20, 25, and 30 were generally synthesized from the allyl amide or ester by treatment with 3-chloroperbenzoic acid (MCPBA). With the exception of 30, which was broken down to unidentified products in refluxing aziridines under a variety of conditions, treatment of these oxiranes with the appropriate aziridines in boiling THF gave the N-substituted aziridines (21, 22, 26, and 27,

(11) Gumennyi, V. I.; Levchenko, A. I.; Panasencko, B. F. *Tr. Vses. Nauchn. Konf. Khim. Tekhnol. Furanykh. Soedin. (Tezisy Dokl.)* 1978, 3, 107; *Chem. Abstr.* 1980, 92, 180901a.

(12) Ohya, A. *Bull. Inst. Chem. Res., Kyoto Univ.* 1956, 34, 25.

(13) Gilman, H.; Burtner, R. R.; Smith, E. W. *Recl. Trav. Chim. Pays-Bas* 1932, 51, 407.

(14) Rinkes, I. J. *Recl. Trav. Chim. Pays-Bas* 1930, 49, 1118.

Scheme III^a

^a Reagents: (i) NaOH/H₂O/EtOH; (ii) Ac₂O/HNO₃; (iii) ethyl chloroformate/allylamine/Et₃N/CH₂Cl₂; (iv) MCPBA/CH₂Cl₂; (v) NaOH/EtOH then allylamine/DCC/THF.

Schemes I and II). Treatment of the oxiranes with unsubstituted aziridine was unsuccessful due to the instability of the products. Treatment of the ester 16 with 2,2-dimethylaziridine gave only the *N*-acyl aziridine 17 by reaction at the carbonyl center of the molecule rather than at the oxirane (Scheme I). 2,2-Dimethylaziridine and stereochemically pure *cis*-2,3-dimethylaziridine were prepared from the appropriately substituted 2-aminoethanols by O-sulfation and elimination with potassium hydroxide, according to the methods of Dickey et al.¹⁵ The potentially bifunctionally alkylating analogue 28 was prepared by reaction of 25 with *cis*-2,3-dimethylaziridine in the presence of MCPBA and triethylamine (Et₃N). Compound 18, with a nonalkylating hydroxyethyl substituent was prepared from the corresponding acyl chloride and the appropriate amine as described. The ring-opened analogue 23 was prepared by treatment of 21 with HBr by methods similar to those we have described elsewhere for a series of 2-nitroimidazoles.⁸

Results and Discussion

The 5-nitrofurans investigated show high radiosensitizing activity in vitro with *C*_{1,6} values of as low as 8 μM for compounds 25 and 26, 5-nitro-2-furanpropanamides with oxiranyl and 2,2-dimethylaziridinyl substituents, respectively (Table I). Generally *C*_{1,6} values of 10–50 μM were found for this series of nitrofurans. These radiosensitizing efficiencies compare favorably with that of compound 3 and all compounds are more efficient radiosensitizers than the nitroimidazoles such as misonidazole and RSU-1069 (1),^{4,5} as would be expected for such highly electron affinic compounds. The less oxidizing 3-nitro analogue, 31, is considerably less effective as a radiosensitizer. With the exception of compounds 25 and 26, which were considerably more potent sensitizers than their nonalkylating analogues, there appears to be little benefit in terms of radiosensitizing efficiency when bifunctional character is introduced in this series of compounds. This is in contrast to the trends observed with nitroimidazoles.

The 5-nitrofurans in this study showed some selective activity in the assay used for direct bioreductive cytotoxicity. The highest ratios of air to nitrogen toxicity (*C*₅₀(air)/*C*₅₀(N₂)) are displayed by those compounds having aziridinyl or (bromoethyl)amino substituents, but these ratios are lower than those observed in our previous studies

Table I. Physicochemical and in Vitro Biological Data of Nitrofurans and Selected Nitroimidazoles

compound	- <i>E</i> ₇ ¹ , mV	radiosensitization: ^a <i>C</i> _{1,6} , mM	<i>C</i> ₅₀ ^b , mM		d tox ^c
			air	N ₂	
misonidazole	389 ^d	0.3 ^d	45.0	4.0	11.3
1	389 ^e	0.1 ^f	0.3	0.0045	66.6
2	nd ^m	0.1 ^g	2.3 ^h	0.09 ^h	25.6 ^h
3	257 ⁱ	0.05 ^j	1.7	0.2	8.5
15	211 ^k	0.05	0.1	0.025	4.0
16	268 ^k	0.025	0.2	0.075	2.7
17	nd	0.1	0.18	0.18	1.0
18	220 ^k	0.05	0.25	0.12	2.1
19	nd	0.05	0.08	0.045	1.8
20	241 ^k	0.02	0.05	0.05	1.0
21	nd	0.04	0.15	0.075	2.0
22	219 ^k	0.05	0.06	0.02	3.0
23	nd	0.03	0.14	0.025	5.6
24	nd	0.03	0.06	0.025	2.4
25	252 ^k	0.008	0.03	0.01	3.0
26	nd	0.008	0.045	0.01	4.5
27	231 ^k	0.035	0.07	0.04	1.8
28	335 ^k	0.025	0.012	0.012	1.0
29	325 ^k	0.075	0.35	0.8	0.4
30	327 ^k	0.04	0.1	0.1	1.0
31	>600 ^k	nd ^l	0.015	0.03	0.5

^a *C*_{1,6} = molar concentration of the compound required to give a sensitizer enhancement ratio (ER) of 1.6. Hence the lower the value of *C*_{1,6} the greater is the sensitizing efficiency. ^b *C*₅₀ (Air or N₂) = concentration required to reduce optical density by 50% in the MTT assay (proportional to cell killing).²⁰ ^c d tox = differential toxicity; *C*₅₀ (air)/*C*₅₀ (N₂) (mean of at least three experiments). ^d Data taken from ref 3. ^e Data taken from ref 21. ^f Data taken from ref 7. ^g Data taken from ref 8. ^h These values are concentrations required to reduce cell survival to 1%.⁸ ⁱ Data taken from ref 22. ^j Data taken from ref 2. ^k Referred to the normal hydrogen electrode (NHE) using benzyl viologen as redox couple; [BV²⁺/BV^{•+}] = -354 mV. ^l Not determined due to toxicity. ER = 1.4 at 0.02 mM. ^m nd = not determined.

with nitroimidazoles. For example, compounds bearing the 2,2-dimethylaziridine substituent (21 and 26) are 5–10 times less effective as hypoxia-selective cytotoxins than is the corresponding nitroimidazole analogue α-((2,2-dimethyl-1-aziridinyl)methyl)-2-nitro-1*H*-imidazole-1-ethanol (RSU-1150).⁷ The most potent compound showing direct hypoxia-selective cytotoxic properties is the (2-bromo-1,1-dimethylethyl)amino compound 23, with a differential toxicity ratio of 6. This is a comparable differential to that found for the known nitrofuran, nitrofurazone 3, but the oxic and hypoxic toxicities are 10 times higher. With the exception of 25, differential cytotoxicity was not shown by the corresponding oxiranes.

The toxicities of these compounds towards oxic cells are at least 1 order of magnitude greater than are the toxicities of similar nitroimidazoles, a property which could account for the poor differentials observed. High oxic toxicities could be related to high one-electron reduction potentials,² coupled with alkylating moieties. However, a number of compounds (15, 18, 19, and 24) have higher toxicities than 3 despite comparable electron-affinities and similarly do not possess alkylating moieties. It therefore appears that other factors are contributing towards toxicity in this series of furans. One-electron reduction potentials (*E*₇¹) measured at pH 7 for a selection of the 5-nitrofuran-2-carboxamides and propanamides using a pulse-radiolytic method were found to be between -210 and -270 mV, ie; 100–150 mV more positive than the nitroimidazoles (Table I). There is some variation in *E*₇¹ with changes in the side chain at the 2-position. The compounds bearing aziridinyl groups are more electron affinic than their oxiranyl analogues, but sensitizing efficiency was unaffected by these changes. In view of the high oxic toxicity and poor hypoxia selectivity that appears to be related to highly positive *E*₇¹, the re-

(15) Dickey, F. H.; Fickett, W.; Lucas, H. J. *J. Am. Chem. Soc.* 1952, 74, 944.




Figure 2. Evaluation of nitrofurans as radiosensitizers in vivo.

duction potential was lowered to below -300 mV by the synthesis of analogues bearing the functionalized side chain at the 3-position and a methyl group at the 2-position (compounds **29** and **30**). These analogues were less toxic than the corresponding 2-carboxamides but showed no improvement in differential toxicity. Compound **28**, in which the conjugation between the furan ring and propenamide side chain (present in compounds **24–27**) was removed by epoxidation, had a greatly lowered E_7^1 of -335 mV. This analogue, however, showed a slight increase in both aerobic and anaerobic toxicity over **24–27**, probably due to the presence of two potential alkylating moieties and showed no hypoxia selectivity. The only 3-nitro analogue synthesized, **31**, showed no differential cytotoxicity towards hypoxic cells and in fact displayed slightly higher oxidic toxicity. The E_7^1 was measured for this compound and found to be <-600 mV. Further 3-nitro analogues of this type were therefore not investigated in view of probable similarly low electron affinities.

Despite promising in vitro radiosensitization results with this series of nitrofurans, and some improvement over nitrofurazone(**3**), they were ineffective as radiosensitizers of murine KHT tumors in vivo (Figure 2), and no greater killing of cells could be achieved than was apparent with radiation alone. Indeed, slight radioprotection appeared to occur 5–15 min after administration of **18**, **20**, and **25**, possibly as a consequence of unknown physiological effects of these agents. Only **16** showed a consistent but small radiosensitizing effect. Together with possible poor distribution and tumor uptake, the ineffectiveness of the compounds as radiosensitizers in vivo could be a consequence of rapid metabolism and/or interactions of the compounds with noncritical targets in the animals, as has been postulated previously with some other nitrofurans.^{16,17} This could involve, for example, the reaction of metabolized nitrofurans with cellular thiol groups, although in culture medium we have not found these compounds to be reactive towards the thiols glutathione and *N*-acetylcysteine.

In conclusion, these nitrofurans show little promise as mixed-function radiosensitizers of clinical potential unless the high oxidic toxicity can be overcome and significant radiosensitizing activity in vivo can be demonstrated. It

is pertinent to note, however, that the doses of the nitrofurans which could be administered to mice were relatively low compared to doses used for similar nitroimidazoles, even with those compounds which were not limited by poor solubility. The relatively high toxicity of these compounds toward oxidic cells in vitro may lead to dose-limiting toxicity towards normal tissues in vivo. The design of nitrofurans and other nitroheteroarenes with lower (more negative) E_7^1 values may reduce oxidic toxicity and could lead to greater hypoxia selectivity. This approach is currently being investigated in this laboratory.

Experimental Section

Chemical Synthesis. NMR Spectra were obtained at 60 MHz with a Jeol PMX60SI spectrometer with SiMe₄ as internal standard. Mass spectra were carried out on a Finnigan 4500 instrument in the electron-impact mode. Melting points are corrected. CH₂Cl₂ was purified by passing through basic alumina, drying over CaCl₂, and distilling prior to use. Tetrahydrofuran (THF) was distilled from CaH₂; other solvents were unrefined commercial grades unless stated otherwise. Commercially available 3-chloroperbenzoic acid (MCPBA) was further purified by washing with phosphate buffer (pH 7) and drying the residue at reduced pressure in the presence of P₂O₅. Elemental analyses were determined by Elemental Microanalysis Ltd., Okehampton, UK. Solutions in organic solvents were dried by treatment with anhydrous Na₂SO₄ and filtration. Solvents were removed by evaporation under reduced pressure. All compounds were racemic. The one-electron reduction potentials (E_7^1) of selected compounds (Table I) were determined by using pulse-radiolysis techniques as previously described.¹⁸

Prop-2-enyl 5-Nitrofuran-2-carboxylate (15). 5-Nitro-2-furoyl chloride (0.5 g, 2.85 mmol) in CH₂Cl₂ (3 mL) was added to allyl alcohol (1.4 g, 24 mmol) and Et₃N (3 mL) in CH₂Cl₂ (5 mL) at 0 °C under N₂. The solution was stirred at 0 °C for 1 h, poured onto ice (50 g), and extracted with CH₂Cl₂ (50 mL). The organic layer was washed with 5% aqueous NaHCO₃ and H₂O and dried. The solvent was evaporated, and the residue was recrystallized from EtOH to give **15** (0.35 g, 62%) as pale yellow prisms: mp 71–71.5 °C; NMR (CDCl₃) δ 4.8 (d, J = 6 Hz, 2 H, allylic CH₂), 5.2–6.2 (m, 3 H, olefinic-H), 7.25 (s, 2 H, furan-H). Anal. (C₈H₇NO₆) C, H, N.

Oxiranylmethyl 5-Nitrofuran-2-carboxylate (16). Dried 3-chloroperbenzoic acid (7.3 g, 42 mmol) in CH₂Cl₂ (75 mL) was added to **15** (3.5 g, 17.7 mmol) in CH₂Cl₂ (30 mL). The solution was heated under gentle reflux for 1.5 h before being washed with 10% aqueous Na₂SO₃ (100 mL), 5% aqueous NaHCO₃ (twice), H₂O, and saturated aqueous NaCl. The organic layer was then dried, and the solvent was evaporated. The residue was recrystallized from EtOH to give **16** (2.3 g, 61%) as a colorless solid: mp 98–99 °C; NMR (CDCl₃) δ 2.7 (dd, J = 4.5 and 3 Hz, 1 H) and 2.9 (t, J = 4.5 Hz, 1 H), oxiranyl 3-CH₂, 3.25 (m, 1 H, oxiranyl 2-H), 4.2 (dd, J = 12 and 6 Hz, 1 H), and 4.7 (dd, J = 12 and 3 Hz, 1 H), CO₂CH₂, 7.25 (s, 2 H, furan-H). Anal. (C₈H₇NO₆) C, H, N.

2,2-Dimethyl-1-(5-nitro-2-furoyl)aziridine (17). Epoxide ester **16** (1.0 g, 5 mmol) was stirred at 20 °C with 2,2-dimethylaziridine (4.0 g, 56.3 mmol) for 5 h. Excess aziridine was then evaporated, and the residue was recrystallized from EtOH to give **17** (0.6 g, 57%) as a pale yellow solid: mp 104–106 °C dec; NMR (CDCl₃) δ 1.5 (s, 6 H, aziridine-(CH₃)₂), 2.45 (s, 2 H, aziridine CH₂), 7.2 (d, J = 3.5 Hz, 1 H, furan-H), 7.3 (d, J = 3.5 Hz, 1 H, furan-H). Anal. (C₉H₁₀N₂O₄) C, H, N.

***N*-(1,1-Dimethyl-2-hydroxyethyl)-5-nitrofuran-2-carboxamide (18).** 5-Nitro-2-furoyl chloride (1.5 g, 8.6 mmol) in CH₂Cl₂ (10 mL) was added to 2-amino-2-methylpropan-1-ol (10 mL, ca. 100 mmol) and Et₃N (10 mL) in CH₂Cl₂ (30 mL). The mixture was stirred at 25 °C for 0.5 h and was then washed with H₂O and dried. The solvent was evaporated, and the residue was recrystallized twice from CH₂Cl₂ to afford **18** (1.35 g, 69%) as a colorless solid: mp 110–112 °C; NMR (CDCl₃) δ 1.4 (s, 6 H, (CH₃)₂), 3.65

(16) Agnew, D. A.; Skarsgard, L. D. *Radiat. Res.* 1974, 57, 246.

(17) Sutherland, R. M.; Durand, R. E. *Int. J. Radiat. Biol.* 1972, 22, 613.

(18) Wardman, P.; Clarke, E. D. *J. Chem. Soc., Faraday Trans. 1* 1976, 72, 1377.

(s, 2 H, CH₂OH), 6.5 (br, 1 H, NH), 7.2 (d, *J* = 3.5 Hz, 1 H, furan-H), 7.3 (d, *J* = 3.5 Hz, 1 H, furan-H). Anal. (C₉H₁₂N₂O₅) C, H, N.

5-Nitro-*N*-(prop-2-enyl)furan-2-carboxamide (19). 5-Nitro-2-furoyl chloride (5.0 g, 28.5 mmol) in CH₂Cl₂ (50 mL) was added dropwise to allylamine (12 mL, 276 mmol) and Et₃N (30 mL) in CH₂Cl₂ (50 mL) at 0 °C under N₂, and the solution was stirred at 0 °C for a further 0.75 h. The mixture was washed with 5% aqueous NaHCO₃ and saturated aqueous NaCl and was dried. Evaporation of the solvent and recrystallization from EtOH gave **19** (3.3 g, 59%) as pale yellow needles: mp 64–65.5 °C; NMR (CDCl₃) δ 4.1 (br t, *J* = 6 Hz, 2 H, allylic CH₂), 5.2 (br d, *J* = 13 Hz, 1 H) and 5.3 (br d, *J* = 17 Hz, 1 H) olefinic CH₂, 5.6–6.2 (m, 1 H, allylic 2-H), 7.0 (br, 1 H, NH), 7.25 (d, *J* = 3.5 Hz, furan-H), 7.35 (d, *J* = 3.5 Hz, furan-H). Anal. (C₈H₈N₂O₄) C, H, N.

***N*-(Oxiranylmethyl)-5-nitrofuran-2-carboxamide (20).** Epoxidation of **19** was carried out as described for the preparation of **16**. The product was recrystallized from EtOH to afford **20** (1.14 g, 53%) as colorless prisms: mp 110–112 °C; NMR (CDCl₃) δ 2.6–4.1 (m, 5 H, oxirane-CH₂ and oxiranyl-H), 6.9 (br, 1 H, NH), 7.2 (d, *J* = 3.5 Hz, furan-H), 7.3 (d, *J* = 3.5 Hz, furan-H). Anal. (C₈H₈N₂O₅) C, H, N.

***N*-(3-(2,2-Dimethyl-1-aziridinyl)-2-hydroxypropyl)-5-nitrofuran-2-carboxamide (21).** Epoxide **20** (0.2 g, 0.94 mmol) was heated under reflux with 2,2-dimethylaziridine (0.2 g, 2.8 mmol) and Et₃N (0.03 mL) in THF (3 mL) for 5 h. The solvent was then evaporated, and the residue was purified by chromatography (silica gel (75 g); EtOH/Et₃N (99:1, v/v)). Recrystallization from EtOH/Et₃N (99:1) afforded **21** (0.07 g, 26%) as a pale yellow solid: mp 94–95 °C; NMR (CDCl₃) δ 1.2–1.3 (m, 7 H, aziridine-(CH₃)₂ and aziridine-H), 1.85 (d, *J* = 3 Hz, 1 H, aziridine-H), 2.3–2.6 (m, 2 H, CHCH₂ aziridine), 3.6–3.9 (m, 4 H, NHCH₂CHOH), 7.20 (d, *J* = 3.5 Hz, furan-H), 7.25 (d, *J* = 3.5 Hz, furan-H), 7.8 (br, 1 H, NH). Anal. (C₁₂H₁₇N₃O₅) C, H, N.

***N*-(3-(*cis*-2,3-Dimethyl-1-aziridinyl)-2-hydroxypropyl)-5-nitrofuran-2-carboxamide (22).** Epoxide **20** was treated with *cis*-2,3-dimethylaziridine as for the preparation of **21** above to give **22** (0.32 g, 32%) as a pale yellow solid: mp 87–89 °C; NMR (CDCl₃) δ 1.2 (d, *J* = 6 Hz, 6 H, 2 × aziridine-CH₃), 1.5 (m, 2 H, 2 × aziridine-H), 2.3 (dd, *J* = 13 and 5 Hz, 1 H), and 2.45 (dd, *J* = 13 and 5 Hz, 1 H) CHCH₂ aziridine, 3.6–4.0 (m, 4 H, NHCH₂CHOH), 7.15 (d, *J* = 3.5 Hz, furan-H), 7.25 (d, *J* = 3.5 Hz, furan-H), 7.7 (br, 1 H, NH); MS, *m/z* 284 (M + H)⁺, 266, 240, 139, 84 (100). Anal. (C₁₂H₁₇N₃O₅) C, H, N.

***N*-(3-(2-Bromo-1,1-dimethylethyl)amino)-2-hydroxypropyl)-5-nitrofuran-2-carboxamide Hydrobromide (23).** Aziridine **21** (0.1 g, 0.35 mmol) was treated with 48% aqueous HBr (2 mL) at 25 °C for 10 min, and the excess reagent was evaporated under reduced pressure at 40 °C. H₂O (2 mL) was added and was evaporated; this operation was repeated. A small volume of EtOH was added to the residue, and the product was precipitated with Et₂O and recrystallized from aqueous acetone to afford **23** (0.05 g, 40%) as a yellow solid: mp 115–117 °C; NMR (CDCl₃) δ 1.8 (s, 6 H, (CH₃)₂), 3.4 (m, 2 H, CHCH₂⁺NH₂), 3.8–4.5 (m, 4 H, NHCH₂CHOH), 4.2 (s, 2 H, CH₂Br), 7.6 (s, 2 H, furan-H). Anal. (C₁₂H₁₉N₃O₅Br_{0.5}H₂O) C, H, N.

3-(5-Nitrofuran-2-yl)-*N*-(prop-2-enyl)propenamide (24). 5-Nitro-2-furaldehyde (5.4 g, 40 mmol) and dry powdered NaOAc (2.0 g, 40 mmol) were added to acetic anhydride (10 mL), and the mixture heated was at 140–150 °C for 2.5 h. The dark solution was then cooled to 80 °C, and H₂O (100 mL) was added, together with decolorizing charcoal, and the solution was boiled under reflux for 10 min. The hot solution was filtered and acidified with 2 M aqueous HCl. Cooling afforded 3-(5-nitrofuran-2-yl)propenoic acid (4.2 g, 57%) as a pale brown solid: mp 228–230 °C, (lit.¹⁹ mp 235–236 °C). This material (1.83 g, 10 mmol) was boiled under reflux in SOCl₂ (3 mL) and dimethylformamide (0.1 mL) for 3.5 h. The SOCl₂ was evaporated, and the resulting acyl chloride, in CH₂Cl₂ (20 mL), was added dropwise under N₂ to allylamine (5 mL, ca. 70 mmol) and Et₃N (12 mL) in CH₂Cl₂ (20 mL) at 0 °C. The solution was stirred at 0 °C for 1.5 h before being washed with H₂O, 5% aqueous NaHCO₃, and saturated aqueous NaCl and dried. The solvent was removed, and the residue was twice

recrystallized from CH₂Cl₂ to give **24** (1.1 g, 50%) as pale yellow needles: mp 168–169 °C; NMR (CDCl₃) δ 4.1 (dt, *J* = 7 and 1 Hz, 2 H, allylic CH₂), 5.20 (br d, *J* = 13 Hz, 1 H), and 5.25 (br d, *J* = 18 Hz, 1 H), and 5.6–6.2 (m, 1 H), CH=CH₂, 6.2 (br t, *J* ≈ 7 Hz, 1 H, NH), 6.7 (d, *J* = 16 Hz, 1 H, furan-CH=CH), 6.7 (d, *J* = 3.5 Hz, 1 H, furan 3-H), 7.3 (d, *J* = 3.5 Hz, 1 H, furan 4-H), 7.4 (d, *J* = 16 Hz, 1 H, furan-CH=CH). Anal. (C₁₀H₁₀N₂O₄) C, H, N.

***N*-(Oxiranylmethyl)-3-(5-nitrofuran-2-yl)propenamide (25).** Epoxidation of **24** (1.0 g, 4.5 mmol) was carried out as described for compounds **16** and **20** but with an extended reaction time of 2.5 h and purification by column chromatography (silica gel; CH₂Cl₂) to afford, after recrystallization from EtOH, **25** (0.5 g, 47%) as yellow needles: mp 175–177 °C; H NMR (CDCl₃) δ 2.65 (dd, *J* = 5 and 3 Hz, 1 H) and 2.85 (t, *J* = 5 Hz, 1 H), and 3.2 (m, 1 H) 3 × oxirane-H, 3.3–4.1 (m, 2 H, NCH₂), 6.3 (br, 1 H, NH), 6.65 (d, *J* = 16 Hz, 1 H, furan-CH=CH), 6.7 (d, *J* = 3.5 Hz, 1 H, furan 3-H), 7.3 (d, *J* = 3.5 Hz, 1 H, furan 4-H), 7.4 (d, *J* = 16 Hz, 1 H, furan-CH=CH); MS, *m/z* 239 (M + H)⁺, 192, 166 (100), 134. Anal. (C₁₀H₁₀N₂O₅) C, H, N.

***N*-(3-(2,2-Dimethyl-1-aziridinyl)-2-hydroxypropyl)-3-(5-nitrofuran-2-yl)propenamide (26).** **25** (0.2 g, 0.84 mmol) was heated with 2,2-dimethylaziridine (0.2 g, 2.8 mmol) and Et₃N (0.03 mL) in THF (3 mL) under reflux for 6 h. The solvent was then removed, and the residue was purified by centrifugally accelerated layer chromatography (silica gel; EtOH/Et₃N (99:1 v/v)) to give **26** (0.15 g, 58%) as a pale yellow solid: mp 149–150 °C; NMR (CDCl₃) δ 1.3–1.5 (m, 7 H, C(CH₃)₂ and aziridine-H), 1.85 (d, *J* = 3 Hz, 1 H, aziridine-H), 2.3–2.6 (m, 2 H, CHCH₂-aziridine), 3.8–4.2 (m, 4 H, NHCH₂CHOH), 6.65 (d, *J* = 16 Hz, 1 H, furan-CH=CH), 6.7 (d, *J* = 3.5 Hz, 1 H, furan 3-H), 7.3 (d, *J* = 3.5 Hz, 1 H, furan 4-H), 7.4 (d, *J* = 16 Hz, 1 H, furan-CH=CH); MS *m/z* 310 (M + H)⁺ (100), 85, 70, 56. Anal. (C₁₄H₁₉N₃O₅·0.33H₂O) C, H, N.

***N*-(3-(*cis*-2,3-Dimethyl-1-aziridinyl)-2-hydroxypropyl)-3-(5-nitrofuran-2-yl)propenamide (27).** Epoxide **25** was treated with *cis*-2,3-dimethylaziridine as for the preparation of **26** above to afford, after recrystallization from EtOH, **27** (0.15 g, 48%) as a yellow solid: mp 145–146 °C; NMR (CDCl₃) δ 1.2 (d, *J* = 6 Hz, 6 H, 2 × aziridine-CH₃), 1.6 (m, 2 H, 2 × aziridine-H), 2.5 (m, 2 H, CHCH₂-aziridine), 3.1–3.8 (m, 4 H, NHCH₂CHOH), 6.65 (d, *J* = 16 Hz, 1 H, furan-CH=CH), 6.7 (d, *J* = 3.5 Hz, 1 H, furan 3-H), 7.3 (d, *J* = 3.5 Hz, 1 H, furan 4-H), 7.4 (d, *J* = 16 Hz, 1 H, furan-CH=CH) 7.5 (br, 1 H, NH). Anal. (C₁₄H₁₉N₃O₅·0.33H₂O) C, H, N.

***N*-(3-(*cis*-2,3-Dimethyl-1-aziridinyl)-2-hydroxypropyl)-2,3-epoxy-3-(5-nitrofuran-2-yl)propenamide (28).** A crude sample of **25** (0.5 g, ca. 2.4 mmol) and 3-chloroperbenzoic acid (0.5 g, 2.9 mmol) was boiled under reflux with Et₃N (0.24 mL) and *cis*-2,3-dimethylaziridine (0.4 mL, ca. 8 mmol) in THF (6 mL) for 6 h. The solvent and excess aziridine were then evaporated. The residue was subjected to column chromatography (silica gel; EtOAc/Et₃N (99:1, v/v)) and recrystallization from EtOH to give **28** (0.25 g, 34%) as a yellow solid: mp 74–75 °C; NMR (CDCl₃) δ 1.2 (d, *J* = 6 Hz, 6 H, 2 × aziridine-CH₃), 1.6 (m, 2 H, 2 × aziridine-H), 2.5–2.6 (m, 2 H, CHCH₂-aziridine), 2.7–4.0 (m, 6 H, NHCH₂CHOH and 2 × oxirane-H), 6.5 (d, *J* = 3.5 Hz, 1 H, furan 3-H), 7.05 (br, 1 H, NH), 7.25 (d, *J* = 3.5 Hz, 1 H, furan 4-H). Anal. C₁₄H₁₉N₃O₆ C, H, N.

2-Methyl-5-nitro-*N*-(prop-2-enyl)furan-3-carboxamide (29). 2-Methyl-5-nitrofuran-3-carboxylic acid (prepared according to the methods of Gilman et al.¹³) (2.0 g, 11.7 mmol) was stirred for 1.5 h at 0 °C with ethyl chloroformate (1.26 g, 11.7 mmol) and Et₃N (1 mL) in CH₂Cl₂ (20 mL). Allylamine (2.0 g, 35.1 mmol) was then added and stirring continued for 1 h at 0 °C. The solution was then poured onto ice (50 g), stirred for 0.5 h, and extracted with Et₂O (2 × 50 mL). The combined organic extracts were washed with 10% aqueous NaHCO₃ (twice) and H₂O and dried, and the solvent was removed. The residue was twice recrystallized from EtOH to give **29** (1.5 g, 61%) as colorless needles: mp 100–101 °C; NMR (CDCl₃) δ 2.8 (s, 3 H, furan-CH₃), 4.1 (br t, *J* = 6.5 Hz, 2 H, allylic-CH₂), 5.05–6.3 (m, 3 H, CH=CH₂), 6.35 (br, 1 H, NH), 7.45 (s, 1 H, furan 4-H). Anal. (C₉H₁₀N₂O₄) C, H, N.

***N*-(Oxiranylmethyl)-2-methyl-5-nitrofuran-3-carboxamide (30).** Oxirane **30** was prepared as described for compounds

Table II. In Vivo Studies. Maximum Doses Administered to Mice

compound	vol injected per 25 g of body wt, mL	max dose, mmol kg ⁻¹ ^c	limiting factor
16	1.0	0.12 (25 mg kg ⁻¹)	solubility ^a
18	0.5	0.44 (100 mg kg ⁻¹)	toxicity ^b
20	0.5	0.24 (50 mg kg ⁻¹)	toxicity ^b
25	1.0	0.11 (25 mg kg ⁻¹)	solubility ^a

^a Injected as suspensions. ^b No acute, severe, or persistent physical or behavioral effects were apparent in C3H/He mice with any of the doses shown in the table. However, following injection of 18, piloerection, an increased respiration rate, and decreased locomotor activity were observed in the mice for approximately 1 h after injection. After higher doses of any of the drugs limited by toxicity severe tremors and convulsions occurred, from which the mice did not recover. ^c Injected ip.

16 and 20 from 0.5 g (2.5 mmol) of 29. Recrystallization from EtOH gave 30 (0.3 g, 53%) as colorless needles: mp 129–130 °C; NMR (CDCl₃) δ 2.8 (s, 3 H, furan-CH₃), 2.75–4.1 (m, 5 H, NCH₂ and 3 × oxirane-H), 6.5 (br, 1 H, NH), 7.45 (s, 1 H, furan 4-H). Anal. (C₉H₁₀N₂O₅) C, H, N.

2-Methyl-3-nitro-*N*-(prop-2-enyl)furan-5-carboxamide (31). 2-Methyl-3-nitrofuran-5-carboxylate (prepared by the method of Rinkes¹⁴) (0.25 g, 1.4 mmol) was stirred with allylamine (3 mL, 69 mmol) and dicyclohexylcarbodiimide (2.1 g, 10 mmol) in THF (7 mL) at 25 °C for 12 h. Excess amine was then evaporated after filtration and the residue was purified by chromatography (silica gel; EtOAc/CHCl₃ (1:1, v/v)) to give 31 (0.1 g, 35%) as pale yellow prisms: mp 55–56 °C; NMR ((CD₃)₂SO) δ 2.6 (s, 3 H, furan-CH₃), 4.0 (m, 2 H, allylic CH₂), 5.2–5.8 (m, 3 H, CH=CH₂), 7.6 (s, 1 H, furan 4-H), 8.5 (br t, *J* = 7 Hz, 1 H,

NH). Anal. (C₉H₁₀N₂O₄) C, H, N.

Biological Methods. The radiosensitization studies in vitro were carried out as described previously with use of Chinese hamster V79-379A cells.⁸ The methods for determining selective toxicity to hypoxic V79-379A cells using the MTT assay are also described elsewhere.²⁰

On the basis of results from experiments in vitro, compounds 16, 18, 20, and 25 were selected for evaluation in vivo in C3H/He mice. The compounds were injected as suspensions or solutions in phosphate-buffered saline (pH 7.3). TLC analyses were carried out to show that the compounds were unchanged at the time of injection. Initial studies were carried out to determine the maximum doses of compounds which could be administered (Table II). Subsequently, the maximum single doses of each compound which could be administered (according to toxicity or solubility) were injected at various times (5–90 min) before local irradiation of subcutaneous KHT sarcomas with a 10-Gy dose of X-rays. Tumors were excised 24 h later and clonogenic assays performed in vitro to determine the survival of tumor cells.⁸

Acknowledgment. Financial support from the British Technology Group is gratefully acknowledged. We thank Dr. M. A. Stier and Dr. M. J. Suto of Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, MI 48105, for the mass spectroscopic data.

- (20) Stratford, I. J.; Stephens, M. A. *Int. J. Radiat. Oncol. Biol. Phys.* 1989, 16, 973.
- (21) O'Neill, P.; Jenkins, T. C.; Stratford, I. J.; Silver, A. R. J.; Ahmed, I.; McNeil, S. S.; Fielden, E. M.; Adams, G. E. *Anti-Cancer Drug Des.* 1987, 1, 271.
- (22) Wardman, P.; Clarke, E. D. *Biochem. Biophys. Res. Comm.* 1976, 69, 942.

Inhibition of Human Leukocyte Elastase. 1. Inhibition by C-7-Substituted Cephalosporin *tert*-Butyl Esters

James B. Doherty,*† Bonnie M. Ashe,‡ Peter L. Barker,†§ Thomas J. Blacklock,|| John W. Butcher,|| Gilbert O. Chandler,† M. Ellen Dahlgren,‡ Philip Davies,‡ Conrad P. Dorn, Jr.,† Paul E. Finke,† Raymond A. Firestone,†¶ William K. Hagmann,† Thomas Halgren,‡ Wilson B. Knight,¶ Alan L. Maycock,‡,¶ Manuel A. Navia,‡,¶ Laura O'Grady,† Judith M. Pisano,† Shrenik K. Shah,† Kevan R. Thompson,† Hazel Weston,† and Morris Zimmerman†

Departments of Medicinal Chemical Research, Biochemistry of Inflammation Research, Enzymology, Process Chemistry Research, Molecular Systems, and Biophysics Research, Merck Sharp and Dohme Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065. Received July 24, 1989

Time-dependent inhibitors of the enzyme human leukocyte elastase have been developed based on the cephem nucleus. A series of cephalosporin *tert*-butyl esters has been examined, and the activity of these compounds has been found to be very sensitive to C-7 substituents, with small, α -oriented, electron-withdrawing groups showing greatest activity. Additionally, the oxidation state of the sulfur atom has been found to play a role in potency, with sulfones showing considerably greater activity than the corresponding sulfides or β -sulfoxides. The α -sulfoxides were inactive.

The azurophilic granules of human polymorphonuclear leukocytes (PMN) contain a serine protease referred to as

human leukocyte elastase (HLE EC 3.4.21.37) because of its ability to degrade elastin in addition to a number of other connective-tissue substrates.¹ The possible pathological consequences of the release of HLE from the PMN into the extracellular environment have been the subject of considerable research and speculation for the past 25 years.^{2,3} Substantial effort has gone into the study of the interaction of HLE with the major naturally occurring protease inhibitor of plasma, α_1 -protease inhibitor (α_1 -PI).⁴ In particular, α_1 -PI is considered the primary

† Department of Medicinal Chemical Research.

‡ Department of Biochemistry of Inflammation Research.

§ Present address: Genentech, Inc., So. San Francisco, CA 94080.

|| Process Research Department.

¶ Molecular Systems Department.

¶ Present address: Bristol-Myers Squibb, 5 Research Pkwy, P.O. Box 5100, Wallingford, CT 06492-7660.

° Department of Enzymology.

° Present address: Sterling Research Group, Malvern, PA 19355.

* Department of Biophysical Chemistry.

¶ Present address: Vertex Pharmaceuticals, 40 Alston St., Cambridge, MA 02139-4211.

(1) Starkey, P. M.; Barrett, A. J. *Biochem. J.* 1976, 155, 265.

(2) Laurell, C. B.; Eriksson, S. *Scand. J. Clin. Invest.* 1963, 15, 132.

(3) Janoff, A. *Am. Rev. Respir. Dis.* 1985, 132, 417.

(4) Morrison, H. *Clin. Sci.* 1987, 72, 151.